A new biotech called Bionyra has launched with $165 million to develop a next generation of drugs for common immune conditions, according to Endpoints News and BioPharma Dive.
The company is led by Frédéric Marrache, who Endpoints News reports previously worked as an immunology and inflammation development executive at the pharmaceutical giant Sanofi. BioPharma Dive describes him as a former Sanofi immunology R&D head and says Bionyra was co-founded by the venture firm Sofinnova Partners.
According to Endpoints News, Marrache assembled a "who's who" of investors and pulled together three drug candidates sourced from biotechs in China and the United States. Those candidates were selected after scanning roughly 100 global assets, the outlet reports.
Bionyra's focus is the TL1A field, an area of growing interest in drug development for immune and inflammatory diseases. BioPharma Dive reports the company is testing new biologics — drugs made from living systems rather than simple chemicals — against widespread immune disorders.
The strategy on display is notable: rather than discovering molecules from scratch, Bionyra is licensing or acquiring promising candidates that already exist elsewhere, including from Chinese biotech firms, and betting it can advance them faster.
Why it matters: a large, investor-backed launch built around already-developed assets shows how the pharmaceutical industry is increasingly racing to commercialize crowded but promising drug targets like TL1A, often by sourcing science globally rather than building it in-house.